Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05039515 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
A Phase 2 study of Fibrodysplasia Ossificans Progressiva, sponsored by Clementia Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT05039515 is a Phase 2 study of Fibrodysplasia Ossificans Progressiva that is active but no longer recruiting, run by Clementia Pharmaceuticals. The registered enrollment target is 113 participants, above the 76-participant average among 4 other Fibrodysplasia Ossificans Progressiva trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05039515, a Phase 2 study of Fibrodysplasia Ossificans Progressiva, is active but no longer recruiting, sponsored by Clementia Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to abnormal stiffening and immobility (ankyloses) of major joints with cumulative and irreversible loss of movement and disability. This study will evaluate the efficacy of 2 dosing regimens of IPN60130 in inhibiting new HO volume compared with placebo (a dummy treatment) in adult and paediatric participants with FOP. It will be assessed by a scan (provides internal images of the body) called low dose Whole Body Computed Tomography (WBCT), excluding head. Adults and participants 5 years of age or older are also eligible for a sub study to evaluate HO lesions assessed by another type of scan, Fluorine-18-labelled natrium fluoride Positron Emission Tomography-Computed Tomography (\[18F\]NaF PET-CT ).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IPN60130
Study Locations (20)
Other
- Hospital Italiano de Buenos Aires - Buenos Aires
- Royal North Shore Hospital - New South Wales - Sydney
- University Hospitals Leuven - Leuven
- University of Alberta, Alberta Health Services (AHS) - Edmonton
- University Health Network (UHN), Toronto General Hospital (TGH) - Toronto
- Children's Hospital Capital Institute of Pediatrics (CIP) - Beijing
- Peking Union Medical College Hospital - Beijing
- Shangai Children Medical Center - Shanghai
- Tongi University - Tongi Hospital - Shanghai
- Groupe Hospitalier Necker Enfants Malades - Paris
- Hopital Lariboisiere - Paris
- Irccs Gaslini Institute - Genoa
- Nagoya University Hospital - Nagoya
- Aichi Children's Health and Medical Center - Ōbu
- The University of Tokyo Hospital - Tokyo
- Instituto Nacional De Rehabilitacion - Mexico City
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
- The Perelman School of Medicine - The University of Pennsylvania - Philadelphia
California
- University of California San Francisco (UCSF) - San Francisco
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05039515
The ClinicalTrials.gov registry entry for NCT05039515 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 76-participant average among 4 other Fibrodysplasia Ossificans Progressiva trials with a reported enrollment target (49% higher). The listed sponsor is Clementia Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrodysplasia Ossificans Progressiva appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05039515 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT05039515 about?
NCT05039515 is a clinical study titled "A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).". Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-up...
What is the current status of trial NCT05039515?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2021-12-01. Estimated completion is 2029-03-30.
What conditions does trial NCT05039515 study?
This clinical trial studies the following conditions: Fibrodysplasia Ossificans Progressiva.
What interventions are being tested in trial NCT05039515?
The interventions under investigation include: Placebo (DRUG), IPN60130 (DRUG).
Who is sponsoring clinical trial NCT05039515?
This trial is sponsored by Clementia Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05039515 being conducted?
This trial has 20 study locations across California, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrodysplasia Ossificans Progressiva
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
RECRUITING
-
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
ACTIVE NOT RECRUITING · Phase 3
-
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.